HOME >> BIOLOGY >> NEWS
Progress toward a new remedy for chronic urinary tract infections?

Brussels, Belgium - Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at the Free University of Brussels have recently published results that show promise in the quest for a new remedy for chronic urinary tract infections. The researchers have shown that administration of the sugar Heptyl--D-mannoside can prevent E. coli bacteria from binding to the wall of the urinary tract - which is the first step in the development of the infection.

A widespread problem

Urinary tract and bladder infections are among the most prevalent bacterial infections and can be quite painful. Fifty percent of all women are confronted by these unpleasant infections at some point in their lives. The disorder is an especially severe problem when it becomes chronic - whereby some patients experience symptoms almost continually. The Escherichia coli bacterium is responsible for 80% of these urinary tract infections. Treatment with antibiotics is possible but does not preclude a recurrence of the infection. In addition to this, more and more bacteria are becoming resistant to the antibiotics. For these reasons, scientists have been busy seeking another solution.

Prevention is better than cure

Julie Bouckaert and her co-researchers, under the direction of Henri De Greve, have discovered a way to prevent E. coli bacteria from adhering to the wall of the urinary tract, so that they can no longer cause infection. Because E. coli bacteria use very particular hair-like projections (called pili) to cling to tissues - the first stage of a potential inflammation - a drug that can prevent this attachment can also avert bladder and urinary tract inflammations.

Combating certain bonds

Bouckaert and De Greve have investigated the way in which the E. coli bacteria attach themselves. This attachment takes place by means of a reaction between the protein 'Adhesine FimH' on the tips of the pili and special receptor
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
10-Feb-2005


Page: 1 2

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress against sarcoma
4. Progress toward artificial photosynthesis?
5. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
6. Progress in battle against life-threatening acute allergy
7. Progress report on Homogeneous Assay project
8. Progress being made in exploring potential use of stem cells to treat heart disease
9. Media Invite: Dinner to award prize for Progress in Cancer Research
10. Progress needed on global regime for access to genetic resources and benefit-sharing
11. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Progress toward new remedy for chronic urinary tract infections

(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cultured from cystic fibrosis patients, scientists at the UNC ... have shown that a new CF drug counteracts the ... The finding, published today in the journal Science ... becomes unstable and loses its ability to function properly ... research offers several insights into how novel CF pharmacotherapies ...
(Date:7/23/2014)... , , , , , ... , , , , , ... that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be to target the... ... , , , , ... , , , , , ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
(Date:7/23/2014)... /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink regimen ... They are the first functional focus beverage to give ... alternative to the temporary fix associated with energy drinks. ... 29, 2014, with hopes to raise $50,000 over the ... http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks were ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
(Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
(Date:7/23/2014)... 23, 2014 With the ability to record ... for more than 15 minutes, Fastec Imaging has brought the ... high speed imaging. “Finally, a high speed camera that can ... in our everyday lives.” proclaims Matt Kearney, VP of Sales ... been to demystify and simplify the traditionally complicated workflow of ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
Cached News: